NX PharmaGen is a leading brand in the field of personalized medicine, dedicated to improving patient care through innovative technologies. Their next-generation molecular diagnostics and imaging products have the potential to revolutionize healthcare outcomes, physician decision-making, and payer economics. With a focus on investing in impactful technologies, NX PharmaGen aims to enhance the lives of patients.

In addition to their cutting-edge products, NX PharmaGen has established subsidiary companies that have made significant contributions to various medical fields. NX Development Corp., a spin-off from NX PharmaGen, successfully secured FDA approval and launched Gleolan, an important imaging tool for brain tumor patients. NX Prenatal Inc., another spin-off, specializes in exosome-based diagnostics for maternal-fetal-infant health, enabling the early detection of biomarker panels predictive of adverse pregnancy outcomes.

The Nexosome Oncology division of NX PharmaGen focuses on utilizing exosome-based diagnostics in the cancer field. By leveraging a liquid biopsy approach, they can identify molecular changes in tumor cells, predicting therapeutic responsiveness and resistance. To learn more about NX PharmaGen and their subsidiaries, please visit their respective websites.

Contact NX PharmaGen for further information